---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-22-000050"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:23:59.757242+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcutis reports Q2 net loss $67.4M; FDA approved ZORYVE for plaque psoriasis

## Summary
- FDA approved ZORYVE (roflumilast cream) for plaque psoriasis in patients 12+; launch expected in coming weeks.
- Positive Phase 3 topline for roflumilast foam in seborrheic dermatitis; NDA submission planned Q1 2023.
- Completed enrollment in INTEGUMENT-1 atopic dermatitis trial; topline data by end of 2022.
- Cash $283.4M at June 30; pro forma ~$570M after $162M equity net + $125M debt draw.
- Q2 net loss $67.4M ($1.31/sh) vs $42.0M ($0.84/sh) in Q2 2021, driven by R&D and G&A increases.

## SEC filing metadata
- accession: 0001787306-22-000050
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000050/0001787306-22-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730622000050/arqt-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-22-000050
- JSON: https://secwatch.observer/filing/0001787306-22-000050.json
- Plain text: https://secwatch.observer/filing/0001787306-22-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.